Niche provided a broad range of services, as a trusted CRO to help Funxional realise its vision for FX125L, as a therapeutic option in a range of chronic inflammatory diseases, including asthma, chronic obstructive pulmonary disease, rheumatoid arthritis and psoriasis. This included clinical trial conduct, submission of clinical trials applications to the MHRA, as well as medical writing for clinical protocols, an Investigational Medicinal Product Dossier and Investigator Brochures. NST’s project management was critical in this partnership. NST integrated seamlessly with Funxional’s team members, paying close attention to project scope and timelines to ensure efficient project delivery.

FX125L targeted a unique inflammatory pathway that was discovered by Funxional. Niche’s clinical expertise was useful in translating this mechanistic knowledge into clinical evidence. The promising findings generated in Niche-supported studies caught the attention of Boehringer Ingelheim, who acquired the rights to FX125L and Funxional’s broader BSCI programme.